skip to content »

Neurology

Houston, Texas

The Cullen Building at Baylor College of Medicine.
Department of Neurology
not shown on screen

Mimi Minh-Ngoc Dang, M.D.

Instructor of Neurology

Clinical Service Area

Neurology

Specialty

Alzheimer's Disease
Memory Disorders

Clinic Appointments

713-798-4734

Consult

713-798-4734

Medical School

M.D., University of Arkansas for Medical Sciences College of Medicine, Little Rock, Ark.

Internship

University of Arkansas for Medical Sciences, Little Rock, Ark.

Residency

Neurology, University of Texas, Southwestern Medical Center at Dallas, Texas

Clinical Fellowship

Alzheimer's Disease and Dementia, Baylor College of Medicine, Houston, Texas

Clinic Location

Baylor Neurology
The Medical Building
1977 Butler Blvd., Suite E5.101
Houston, Texas 77030

Research Projects (Selected out of 11)

  • Olfactory receptor copy number association with age at onset of Alzheimer's disease
  • Phase 3 multicenter, randomized, placebo-controlled, double-bline twelve-month safety and efficacy study evaluating dimebon in patients with mild-to-moderate Alzheimer's disease on Donepezil
  • A double-blind pacebo-controlled preliminary study of the efficacy, safety and tolerability of ST 101 in the treatment of Alzheimer's disease in subjects concurrently receiving donepezil (Aricept) (ST101-A001-202)
  • An open label study of the safety and tolerability of ST101 in subjects with Alzheimer's disease (ST101-A001-401)
  • Concert plus DIM 18 extension: an open-label extension of the concert protocol (DIM18) evaluating Dimebon (Latrepirdine) in patients with Alzheimer's disease
  • A randomized, double-blind, placebo-controlled, parallel-group, multicenter, phase II study to evaluate the efficacy and safety of Crenezumab in patients with mild to moderately Alzheimer's disease
  • A phase 2, multicenter, 24-month, randomized, third party unblinded, placebo-controlled, parallel-group amloid imaging positron emission tomography (PET) and safety trial of ACC-001 and QS-21 adjuvant in subjects with early Alzheimer's disease
  • A phase 2a, multicenter, randomization, double-blind, placebo-controlled, multiple ascending dose, efficacy, safety, tolerability, pharmacokinetic, pharmacodynamic, and immunogenicity trial of AAB-001 in patients with mild to moderate Alzheimer's disease
  • Alzheimer's disease neuroimaging initiative (ADNI-2)
  • Texas Alzheimer's Research and Care Consortium (TARCC)

Contact Information

Mimi Minh-Ngoc Dang, M.D.
Department of Neurology
Baylor College of Medicine
1977 Butler Blvd., Suite E5.101
Houston, Texas 77030

Tel: 713-798-7444
Fax: 713-798-7434
Email:

E-mail this page to a friend